MediPharm Labs Appoints Renowned Medical Expert and Pharmaceutical Researcher Dr. Paul Tam to its Board of Directors
TORONTO, May 01, 2019 (GLOBE NEWSWIRE) --
MediPharm Labs Corp. ... is pleased to announce the appointment of Dr. Paul Tam, MBBS, FRCP(C), FACP to its Board of Directors effective immediately, subject to the necessary regulatory approvals.
In connection with the Company’s goal of satisfying non-venture requirements for corporate governance and financial oversight, Dr. Tam will also replace Chris Hobbs on the Company’s Audit Committee resulting in an Audit Committee fully comprised of independent directors in accordance with National Instrument 52-110 – Audit Committees.
“Dr. Paul Tam is a tremendous addition to our board and will be a valuable independent director and contributor as we continue to deepen our medical expertise through this next phase of growth,” said Patrick McCutcheon, Chief Executive Officer, MediPharm Labs.
“Dr. Tam brings significant pedigree and experience in his field
---> and from his tenure with leading pharmaceutical companies.
We look forward to benefiting from his guidance as we focus on advancing initiatives for the commercial development of high quality, pharmaceutical-like cannabinoid-based products and active pharmaceutical ingredients for a rapidly growing medical and adult-use market.”
With more than three decades of clinical research
---> and medical practice experience,
---> Dr. Paul Tam is a globally recognized expert in the field of nephrology and a pioneer in the development of continuous renal replacement therapy for acute kidney injury.
In 1996, Dr. Tam founded the Scarborough Regional Nephrology Program where he is currently Medical Director of the largest community nephrology program in Canada.
Dr. Tam oversees a team of thirteen nephrologists that provide renal care to over 900 dialysis patients and 4,000 chronic kidney disease patients and is also an active staff nephrologist at The Scarborough Hospital.
Dr. Tam is also the Medical Quality Advisor for three major Independent Health Facilities that provide hemodialysis care.
Dr. Tam has extensive and highly specialized experience in pharmaceutical development
---> having co-founded and acted as the Medical Director overseeing operations and clinical research for a contract research organization which was ultimately acquired by the Biovail Corporation.
Dr. Tam served as a Director of Biovail Corporation after the acquisition and he also served as the Medical Director of Contract Research arm of Biovail Corporation.
---> Dr. Tam continues to be active in clinical research and participate in multi-national trials, product commercialization and is a highly respected subject matter author.
“I’m grateful for the opportunity to join MediPharm Labs’ Board of Directors as the Company continues to lead the way in a brand-new industry that has shown incredible potential to improve people’s lives,” said Dr. Paul Tam.
“I look forward to working with the Board and management team to help grow and shape the future of MediPharm Labs as it focuses on developing cannabis-based derivative products in a rapidly expanding global industry.”
Dr. Tam also leads and serves on multiple professional and executive governance committees.
He is an active member and past Section Chair representing the Nephrology Specialty of the Ontario Medical Association, and active member and past Chair of the Ontario Association of Nephrologists.
---> In the past he has also served on the Boards of Directors for pharmaceutical companies.
---> Dr. Tam received his medical degree from The University of Hong Kong and completed further specialization at the University of Toronto, Canada.